timothy sykes logo
SPRC Stock Draws Traders After Psychedelic IP And Quantum Push Thumbnail
G Google News

SPRC Stock Draws Traders After Psychedelic IP And Quantum Push

MATT MONACO•UPDATED OCT. 15, 2026, 9:20 AM ET
Reviewed by Jack Kelloggand Fact-checked by Tim Sykes

SciSparc Ltd. stocks have been trading up by 17.72 percent following highly positive news driving strong investor optimism.

Key Takeaways

  • NeuroThera, majority-owned by SPRC, reported three new U.S. patent applications combining its PEA technology with LSD, ketamine and ibogaine for depression, PTSD, pain and substance use disorders.
  • Through NeuroThera Labs and partner Clearmind Medicine, SPRC expanded its U.S. IP portfolio with three psychedelic–N-acylethanolamine patent filings, including proprietary palmitoylethanolamide, across multiple CNS and pain indications.
  • CliniQuantum, a NeuroThera subsidiary, used a GPU-accelerated quantum-simulation platform to scan billions of three-gene combinations with roughly 16.8x faster performance than CPU-only systems.
  • The CliniQuantum benchmark showcases strong computational efficiency for SPRC’s quantum-simulation approach but does not yet translate into proven clinical benefit or near-term revenue.

Candlestick Chart

Live Update At 09:19:37 EDT: On Thursday, October 15, 2026 SciSparc Ltd. stock [NASDAQ: SPRC] is trending up by 17.72%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

SciSparc Ltd. (SPRC) is trading like a classic low-priced biotech with story-driven moves and choppy follow-through. Over the recent multi-week stretch, SPRC slid from around $5.21–$5.39 down toward $3.63, a pullback of roughly 30% from late-September levels. That tells traders momentum cooled after a prior spike and the stock is back in “prove it” territory.

Daily candles show a steady grind lower: lower highs from $5.31 and $5.21 down through the low-$4s and now high-$3s. The 5‑minute data reinforces that SPRC trades like a thin name—wide ranges, sharp pops, and quick fades. Pre-market moves from the $4s into the $5s and back down intraday show clear day-trading action and emotional order flow, not steady accumulation.

More Breaking News

On fundamentals, SPRC reported about $0.86M in revenue and trades at roughly 3.03x sales, with price-to-book near 0.61. Book value per share sits around $7.30, meaning the market prices SPRC at a discount to its accounting equity. Return on capital is deeply negative at about -67.36%, reminding traders this is still an early-stage, loss-making biotech story. With around $4.59M in cash and total liabilities near $2.48M, SciSparc has some breathing room, but the real driver for SPRC will remain headlines, not earnings.

Why Traders Are Watching SPRC’s Psychedelic And Quantum Story

SPRC has put itself directly in the crosshairs of two hot narrative lanes: psychedelics and advanced computing. That combination alone is enough to grab traders’ attention in a choppy small-cap market.

On the drug side, SciSparc, through its majority-owned unit NeuroThera, announced three new U.S. patent applications that bolt its PEA technology onto LSD, ketamine and ibogaine. Those filings target heavy-hitting areas like depression, PTSD, pain and substance use disorders. For SPRC, these are paper assets, not yet products. But in biotech trading, paper assets—especially patents—often shape the story and perceived upside.

A second wave of filings, run through NeuroThera Labs and partner Clearmind Medicine, goes after novel combinations of those same psychedelic compounds with N‑acylethanolamines, including SciSparc’s proprietary palmitoylethanolamide. That detail matters. It gives SPRC a differentiating platform angle rather than just “me-too” psychedelic exposure, which is key in a crowded field of micro-cap names chasing similar CNS indications.

Then there’s the quantum piece. NeuroThera’s subsidiary CliniQuantum benchmarked a GPU-accelerated quantum-simulation setup in the cloud, analyzing billions of three-gene combinations from real-world clinical data and clocking roughly 16.8x faster performance than CPU-only runs on an S&P 500 company’s quantum architecture. For traders, this says SPRC isn’t just a drug story, it’s also pushing into computational biology.

The catch is clear: that benchmark proves speed, not clinical benefit or revenue. So SPRC’s quantum angle is optionality, not a cash-flow engine—yet. In trading terms, it adds another narrative lever that can fuel spikes when headlines hit, even though the balance sheet is still driven by traditional biotech timelines.

Conclusion

SPRC sits in a classic speculative zone where headlines drive the chart more than cash flows. The recent stack of psychedelic IP news and the CliniQuantum quantum-simulation benchmark show SciSparc trying to widen its moat—more patents, more platforms, more ways to be perceived as valuable in CNS and pain markets.

For traders, the key is separating story from setup. SPRC’s share price has pulled back from the $5s into the mid‑$3s, even as the company expanded its U.S. IP portfolio and showcased serious computational horsepower. That disconnect is where disciplined trading plans matter. If SPRC holds these lower levels and starts putting in higher lows on rising volume, the fresh patents and quantum buzz give shorts something to think about and momentum traders a clear catalyst narrative.

But none of this is guaranteed to translate into approved drugs or meaningful revenue. As millionaire penny stock trader and teacher Tim Sykes says, “You must adapt to the market; the market will not adapt to you.”. Tim Sykes’s mantra applies directly here: “Trade the price action, not the hype.” SPRC offers hype fuel—psychedelics, quantum, AI-like data crunching—but the only thing that pays traders is managing risk around the actual chart. Treat SciSparc as a high-risk, story-driven ticker for educational and research tracking, not a set‑and‑forget long-term play.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”